https://orcid.org/0000-0003-0968-1001
Figures & data
Table 1 Characteristics of Subjects Between RCC Patients and Control Group
Table 2 Distributions of lncRNA GAS5 Genotypic and Allelic Frequencies Among RCC Patients and Controls
Table 3 Stratified Analysis Between the Genotypes and Alleles of lncRNA GAS5 rs145204276 Polymorphism Among RCC Patients and Control Group
Table 4 Stratified Analysis Between the Genotypes and Alleles of lncRNA GAS5 rs55829688 Polymorphism Among RCC Patients and Control Group
Table 5 Association Between LncRNA GAS5 Genotypes and Clinicopathologic Characteristics of RCC
Figure 1 (A) Relative GAS5 expression in 58 RCC tumor tissue samples and adjacent control tissue samples. (B) Relative GAS5 expression in RCC tumor tissue samples and control samples stratified according to the rs145204276 ins/ins (II) and ins/del + del/del (ID+DD) genotypes. (C) Relative GAS5 expression in RCC tumor tissue samples and control samples stratified according to the rs55829688 TT and TC+CC genotypes. GAPDH served as the normalization control. Data are expressed as medians with interquartile ranges (*P < 0.05, ***P < 0.001, n.s., not significant).
Figure 2 The effect of rs145204267 on GAS5 transcriptional activity shown by luciferase reporter assay. The constructs containing rs145204267 ins or del allele were inserted into the pGL3-basic vector. A498 and HK-2 cells were transfected with the pGL3-basic vector, pGL3-Ins, or pGL3-del, and relative luciferase activity was measured by dual-luciferase reporter assay 24 hours post-transfection. Data are presented as mean ± standard error (*P < 0.05, **P < 0.01).
